<DOC>
	<DOCNO>NCT00103506</DOCNO>
	<brief_summary>The purpose study evaluate time progression , overall survival , response rate safety two open-label treatment group ; DOXIL/CAELYX combination VELCADE vs. VELCADE monotherapy .</brief_summary>
	<brief_title>Study DOXIL/CAELYX ( Pegylated Liposomal Doxorubicin ) VELCADE ( Bortezomib ) VELCADE Monotherapy Treatment Relapsed Multiple Myeloma</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , parallel-group , open-label ( involved people know identity intervention ) , multicenter study 18 country . A total 646 patient multiple myeloma whose disease progress initial response least 1 line prior therapy refractory initial treatment enrol . The primary endpoint time progression ( interval date randomization date disease progression ) ; secondary endpoint overall survival ( interval date randomization patient 's death cause ) , response rate ( proportion patient evaluable population achieve complete partial response ) , safety . Other study endpoint include patient report outcomes exploratory pharmacogenics ( identify genetic marker response ) . Patients assess efficacy safety every 3 week disease progression document 42 week start first dose study drug . Patients , progress 42-week period , assess every 6 week disease progression document . Efficacy evaluation include : serum protein electrophoresis , 24-hour urine collection protein electrophoresis , skeletal survey ( plain film ) , bone marrow biopsy aspirate , clinical radiologic assessment plasmacytoma , serum calcium . Responses progression assess objectively computer algorithm base EBMT criterion . Safety evaluation include adverse event report , change clinical laboratory finding , test cardiac function ( multiple gate acquisition scan/echocardiogram electrocardiogram ) . Group A : VELCADE monotherapy : VELCADE 1.3 milligram per meter square ( mg/m^2 ) administer i.v . bolus Days 1 , 4 , 8 , 11 21-day cycle . Group B : DOXIL/VELCADE combination : treat VELCADE dose schedule specify Group A. DOXIL/CAELYX 30 mg/m^2 intravenous infusion give Day 4 every 21-day cycle follow administration VELCADE .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients multiple myeloma receive least 1 prior therapy either respond later progressive disease progress first therapy ( primary refractory ) eligible study Patients may receive prior doxorubicin cumulative dose 240 milligram per meter square ( mg/m^2 ) doxorubicin , DOXIL , equivalent amount another anthracycline ( i.e. , 1 mg doxorubicin = 1 mg DOXIL/CAELYX = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin ) Must normal cardiac function , evidence leave LVEF within institutional normal limit . History treatment VELCADE progressive disease receive anthracyclinecontaining regimen No change disease status initial therapy No treatment malignancy within past 5 yr ( multiple myeloma ) progressive disease receive anthracyclinecontaining regimen Nonsecretory disease Myocardial infarct within past 6 month No major surgery past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Doxil</keyword>
	<keyword>Caelyx</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Velcade</keyword>
	<keyword>Bortezomib</keyword>
</DOC>